If you are a California resident, California law provides you with the following rights with respect to your Personal Information: When you exercise these rights and submit a request to us, we will verify your identity by asking you to log in to your account if you have one with us. Remove data columns and navigations in order to see much more filing content and tables in one view, Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q, Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis, Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports, Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not, Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity, See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years, or     ... About $9K - $10K/yr Additional Pay. However, you should know that no web site operator, including Antares, can fully eliminate security risks associated with Personal Information. Katherine A. Littrell, PhD, RN Vice President, Investor Relations. Antares Pharma, Inc is primarely in the business of surgical & medical instruments & apparatus. Antares Pharma Inc. ATRS 3.87 0.12 (3.01%). If at any point, we decide to use personally identifiable information or health-related personal information in a manner different from that stated at the time it was collected, you will be given a choice to allow or disallow any additional uses or disclosures of your personally identifiable information or health-related personal information. We have put in place procedures to deal with any suspected Personal Information breach and will notify you and any applicable regulator of a breach where we are legally required to do so. Annual stock financials by MarketWatch. ANTARES PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2019 OPERATING AND FINANCIAL RESULTS, Record Quarterly Revenue of $37.8 Million – Earnings Per Share of $0.03, Record Annual Revenue of $123.9 Million, a 95% Increase over 2018 Annual Revenue, “Our evolution as a pharmaceutical technology company continued in 2019, as we delivered record revenue and the Company’s first full year of operating income. 10 Nov 2020 Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference Read More. The Company reported total revenue of $37.8 million for the fourth quarter of 2019 and $123.9 million for the year ended December 31, 2019. Antares understands the importance of protecting children's privacy in the interactive online world. 1 . Create an account, Consolidated Balance Sheets (Parenthetical), Consolidated Statements Of Comprehensive Loss, Consolidated Statements Of Stockholders' Equity, Summary Of Significant Accounting Policies, Revenues, Significant Customers And Concentrations Of Risk, Summary Of Significant Accounting Policies (Policies), Summary Of Significant Accounting Policies (Tables), Accrued Expenses And Other Liabilities (Tables), Revenues, Significant Customers And Concentrations Of Risk (Tables), Quarterly Financial Data (Unaudited) (Tables), Summary Of Significant Accounting Policies - Additional Information (Detail), Summary Of Significant Accounting Policies - Inventories (Detail), Summary Of Significant Accounting Policies - Components Of Equipment, Molds, Furniture, And Fixtures (Detail), Summary Of Significant Accounting Policies - Summary Of Changes In Reserves For Product Returns And Sales Allowances (Detail), Summary Of Significant Accounting Policies - Additional Information (Detail1), Leases - Summary Of Operating Lease Maturities (Detail), Leases - Summary Of Future Minimum Lease Payments Under Operating Leases (Detail), Accrued Expenses And Other Liabilities - Schedule Of Accrued Expenses And Other Liabilities (Detail), Long-Term Debt - Additional Information (Detail), Long-Term Debt - Schedule Of Future Principal Payments Under Term Loan, Including End Of Term Charge (Detail), Stockholders' Equity - Additional Information (Detail), Share Based Compensation - Additional Information (Detail), Share Based Compensation - Summary Of Stock Option Activity (Detail), Share Based Compensation - Assumptions Used In Fair Value Measurement Of Options Granted (Detail), Share Based Compensation - Schedule Of Performance Stock Unit Awards And Restricted Stock Granted Under Long-Term Incentive Program (Detail), Share Based Compensation - Fair Value Of Psus Granted Determined Using Monte Carlo Simulation (Detail), Share Based Compensation - Summary Of Share Based Compensation Allocation Expense (Detail), Employee 401(K) Savings Plan - Additional Information (Detail), Sale Of Assets - Additional Information (Detail), Income Taxes - Additional Information (Detail), Income Taxes - Schedule Of Income (Loss) Before Income Tax Domestic And Foreign (Detail), Income Taxes - Summary Of Effective Tax Rates Differ From Statutory Income Tax Rates (Detail), Income Taxes - Summary Of Deferred Tax Assets (Liabilities) (Detail), Revenues, Significant Customers And Concentrations Of Risk - Summary Of Revenue Disaggregated By Major Types And Sources (Detail), Revenues, Significant Customers And Concentrations Of Risk - Summary Of Revenues Disaggregated By Customer Geographic Location (Detail), Revenues, Significant Customers And Concentrations Of Risk - Summary Of Significant Customers From Which The Company Derived 10% Or More Of Total Revenue (Detail), Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Detail), Exhibit 4.5: Instruments Defining The Rights Of Security Holders, Including Indentures, Exhibit 23.1: Consents Of Experts And Counsel, Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification, Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification, https://last10k.com/sec-filings/atrs/0001564590-20-008465.htm. 10-k: antares pharma, inc. by published: mar 8, 2016 5:15 p.m. et. Selatogrel, a new chemical entity, is being developed for the treatment of a suspected acute myocardial infarction (AMI) in adult patients with a history of AMI. The information you disclose and provide in interactive services may be linked (pursuant to all applicable laws) with the Personal Information you may choose to provide elsewhere on our site and together this may provide us with Personal Information about your health and health care. Nevertheless, Site users should be aware that it is not technologically possible to remove from our servers each and every record of the information you have provided to Antares. 2016-08-09: EX-10.6 To personalize content provided on the website. Enter Company or Symbol.Press down arrow for suggestions, or Escape to return to entry field. For financial reporting, their fiscal year ends on December 31st. The security of your data is very important to Antares. 04/03/20 PRE 14A Proxy Statement - Notice of Shareholders Meeting (preliminary). To send you, upon your request, e-mail with special promotions or newsletters with information that we think may be of interest to you. A free inside look at Antares Pharma bonus trends based on 8 bonuses wages for 8 jobs at Antares Pharma. 02/14/20 SC 13G/A Amended Statement of Ownership Employer Identification No. ANTARES PHARMA, INC. (Exact name of registrant as specified in its charter) A Delaware corporation I.R.S. Top investors of Antares Pharma stock. Antares Pharma Inc. all SEC filings breakout by MarketWatch. Antares Pharma, Inc. - ‘25’ on 6/25/12 Notice by an Issuer of the Removal from Listing and Registration on a Securities Exchange of Matured, Redeemed or Retired Securities - Seq. Antares Pharma Inc. Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is an emerging specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. Fourth quarter royalty revenue was $6.2 million as compared to $3.5 million reported in the same period last year, a 78% increase. Antares Pharma (Issuer) Powell Fred M (Reporting) Form 4 Statement of changes in … ET by Tomi Kilgore Antares Pharma stock … To create summary data that we will use for our business purposes, including research to improve our products and analyses that may help us better market our products. Partnering with Antares; Devices; For Investors. low after FDA letter late Thursday Oct. 13, 2017 at 7:57 a.m. To customize your site experience by anticipating the information and services that may be of interest to you. About $113K - $123K/yr Avg. All personal and/or health-related personal information is kept physically behind firewalls that prevent intruders from gaining access. Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is an emerging specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies and topical gel-based products. III. If we allow a third party contractor to have access to your Personal Information or health-related personal information, we will not authorize them to take it or use it for any purpose that is not consistent with this Privacy Statement. View the ATRS U.S. Securities and Exchange Commission reporting information. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Antares Pharma, Inc.. Employer Identification No. investorinfo@jazzpharma.com Ireland: +353 1 634 7892 U.S.: +1 650 496 2800 The Site may contain links to other websites. Senior Product Development Engineer. Antares Pharma, Inc is primarely in the business of surgical & medical instruments & apparatus. This Privacy Policy does not address personal information that you provide to us in other contexts (e.g., through a business relationship not handled through the Site). Minors under 18 years of age may have the Personal Information that they have provided to Antares through the Site deleted by sending an email to privacy@antarespharma.com requesting deletion. About $9K - $10K/yr Additional Pay. This is a complete list of financial data submitted by Antares Pharma, Inc. to the Securities and Exchange Commission (SEC) in their recent 10K and 10Q filings. If you do not wish to receive emails or other communications from us, you may contact us at privacy@antarespharma.com and request that your Personal Information be removed from our list.